Search Results

Lysophosphatidic acids (LPAs) are bioactive phospholipids implicated in a wide range of cellular activities that regulate a diverse array of biological functions. They recognize two types of G protein-coupled receptors (LPARs): LPA1-3 receptors and LPA4-6 receptors that belong to the endothelial gene (EDG) family and non-endothelial gene family, respectively. In recent years, the LPA signaling pathway has captured an increasing amount of attention because of its involvement in various diseases, such as idiopathic pulmonary fibrosis, cancers, cardiovascular diseases and neuropathic pain, making it a promising target for drug development. While no drugs targeting LPARs have been approved by the FDA thus far, at least three antagonists have entered phase Ⅱ clinical trials for idiopathic pulmonary fibrosis (BMS-986020 and BMS-986278) and systemic sclerosis (SAR100842), and one radioligand (BMT-136088/18F-BMS-986327) has entered phase Ⅰ clinical trials for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis. This article provides an extensive review on the current status of ligand development targeting LPA receptors to modulate LPA signaling and their therapeutic potential in various diseases. Read full article

The Pattern: Scientific Isolation Scientific Isolation  = when a biotech’s internal activity becomes so dominated by experiments, data nuance, and scientific discourse that the organization loses strategic Why Scientific Isolation Is Dangerous and Expensive This pattern rarely causes a single catastrophic The danger is subtle: 👉Scientific isolation feels busy, intelligent, respectable. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake.

the opportunity of meeting and networking with basically most of the participants. There were several sections, among them one specific for GPCRs. Sometimes when you’re in the field you forget the importance GPCRs holds in drug development as a whole Sharing the round table discussion with these excellent scientists felt like a dream come true, and Maria Session 4 on Wednesday was dedicated to GPCRs.

Science isn’t the problem; scientific thinking is.   ✅  You don’t need to abandon your scientific instincts. Leadership isn’t in your lab notebook; it’s in how you decide     How to Know If You're Still Leading Like a Scientist It’s tempting to refine the deck, rework the roadmap, or re-analyze the market.   ✅ The shift from scientist to CEO  is not about abandoning your expertise.

#technology #lifescience #immunology #antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies pharmaindustry #pharmaceuticals #oncology #healthcare #drugdevelopment" Read more at the source #DrGPCR #GPCR

G protein-coupled receptors (GPCRs) are integral to cellular signaling, influencing a wide array of physiological A study published in Scientific Data by Arne Hansen et a l has introduced a sensitive method for detecting of GPCRs' roles in immune function and potential therapeutic applications. to 206, while platelets exhibit a distinct profile with 69 GPCR mRNAs. abundant and rare GPCR transcripts.

At Alkermes , Sokhom Pin wasn’t just leading GPCR programs; he was building culture from the ground up workflows that encouraged curiosity without burnout He supported work-life balance while maintaining scientific In a field like GPCR research (where data complexity and failure rates are high), scientific rigor thrives GPCR ecosystem , GPCR research community , GPCR podcast , GPCR data platform , GPCR training program

innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR

GPCR Podcast, Dr. Maria Majellaro makes it clear that Celtarys isn’t just a ligand provider. It’s a scientific partner. And that mindset is precisely what makes their new partnership with Dr. GPCR so powerful. “We don’t just deliver compounds, we solve assay problems.” — Dr. . _______________ Keyword Cloud:   GPCR data platform , fluorescent ligands , assay development , GPCR GPCR ecosystem , GPCR webinar series

GPCR Updates   We want your feedback - Help shape the future of Dr. GPCR.   Your voice matters. GPCR Ambassador - Share & refer with Dr. GPCR.   Help grow the GPCR community by joining the Dr. GPCR affiliate program.   — Phosphorylation “Barcodes” Tune β-arrestin Isoform Signaling via Allosteric Networks . GPCR Team

Significant advancements in the cellular biology of G protein-coupled receptors (GPCRs) about a novel research team, led by Brandon Novy and colleagues, utilized an innovative APEX2/AUR biosensor that allows scientists fluorescence serves as a readout for the activity of APEX2 and, by extension, the trafficking of the GPCR The implications of this research extend beyond basic science ; understanding the role of DNAJC13 in GPCR field continues to evolve, this study represents a crucial step toward unraveling the understanding of GPCR

Hello GPCR Innovators ,   We’re preparing to launch Terry’s Corner, a new knowledge hub shaped by Dr. Terry Kenakin’s decades of GPCR insight. delivers selective pain relief in preclinical models Dr.GPCR Updates Terry’s Corner  – Build Better GPCR Stay curious, stay connected, because the future of GPCR science is being written pathway by pathway. GPCR Team

Watch Episode 172 The Bigger Picture: GPCR Science Meets Public Health At its core, Catherine Demery’ For scientists, this means rethinking how we study GPCR-mediated respiratory depression. For scientists, they sharpen our understanding of how different GPCR systems interact to produce respiratory In other words, this is GPCR science with immediate, life-or-death consequences. By tracing those pathways, her research gives scientists, first responders, and policymakers the knowledge

pharmaceutical chemist, Alessandro never imagined himself working at the cutting edge of computational GPCR began their mission: to computationally study olfactory GPCRs , a massively under-characterized group With hundreds of subtypes and limited ligand data, olfactory GPCRs represent a high-risk, high-reward —Alessandro Nicoli Want to explore computational GPCR science yourself? Explore the   GPCR University  or enroll in Terry's Corner for GPCR Courses led by Dr.

In this episode, Catherine reflects on how her identity as a scientist took shape, why she’s committed Like many young scientists, she explored different paths and gained industry experience before realizing Why Catherine Chose Academia At a time when many early-career scientists debate whether to stay in academia her, the opioid crisis isn’t an abstract dataset—it’s a lived experience that informs her drive as a scientist And GPCR pharmacology isn’t just an academic pursuit—it’s essential to understanding and responding to

GPCR Ecosystem Member, you've been with us as we've laid the groundwork for something truly special. GPCR Ecosystem, we're giving Dr. GPCR Premium Members a significantly reduced access  to Terry's Corner for a limited time.   GPCR Team & Terry’s Desk

Yamina’s Corner delivers GPCR consulting that cuts through the noise, designing assay cascades, setting GPCR partner Celtarys Research has validated a TR-FRET assay for cannabinoid receptor ligands using their Read The Full Article GPCR Publication Highlights   Chemokine–GPCR Selectivity Unveiled Sequence- and Distinct Ligand Activation in NMBR Simulations show how two ligands differently activate class A GPCR GPCR Team Join Our Newsletter!

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4 WHIM syndrome is a rare immunodeficiency disorder that is characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. While several gain-of-function mutations that lead to C-terminal truncations, frame shifts and point mutations in the chemokine receptor CXCR4 have been identified in WHIM syndrome patients, the functional effect of these mutations are not fully understood. Here, we report on a new WHIM syndrome mutation that results in a frame shift within the codon for Ser339 (S339fs5) and compare the properties of S339fs5 with wild type CXCR4 and a previously identified WHIM syndrome mutant, R334X. The S339fs5 and R334X mutants exhibited significantly increased signaling compared to wild type CXCR4 including agonist-promoted calcium flux and extracellular signal-regulated kinase activation. This increase is at least partially due to a significant decrease in agonist-promoted phosphorylation, β-arrestin binding, and endocytosis of S339fs5 and R334X compared to wild type CXCR4. Interestingly, there were also significant differences in receptor degradation, with S339fs5 having a very high basal level of degradation compared to that of R334X and wild type CXCR4. In contrast to wild type CXCR4, both R334X and S339fs5 were largely insensitive to CXCL12-promoted degradation. Moreover, while basal and agonist-promoted degradation of wild type CXCR4 was effectively inhibited by the CXCR4 antagonist TE-14016, this had no effect on the degradation of the WHIM mutants. Taken together, these studies identify a new WHIM syndrome mutant, CXCR4-S339fs5, that promotes enhanced signaling, reduced phosphorylation, β-arrestin binding and endocytosis, and a very high basal rate of degradation that is not protected by antagonist treatment. Read full article

This allows him to see how inflammation, cognition, and pain circuits overlap , and how GPCRs might serve And it challenges the GPCR community to use its tools not just to explain, but to intervene. the case for building pain research from the clinic down, not the bench up. ________ Keyword Cloud: GPCR podcast , pain modeling , GPCR online course , translational research , neuroimmune signaling .

Kenakin  will get released next month, featuring real questions from discovery scientists tackling enzyme s Corner and get: Frameworks proven in real discovery programs On-demand lessons  designed for busy scientists GPCR members save 50%+  with your Weekly News code. 👉  Join Terry’s Corner & Secure Your Spot for the Kenakin with your own enzyme or GPCR interaction puzzles.

Neuropeptides and their specific receptors (primarily G protein-coupled receptors, GPCRs) regulate multiple A total of 41 neuropeptide GPCR genes belonging to three classes were also identified. These GPCRs and their probable ligands were predicted. expression patterns of these 98 genes in various larval tissues were evaluated using quantitative real-time PCR to determine physiological functions and pharmacological characterization of neuropeptides and their GPCRs

Class B G protein-coupled receptors (GPCRs) are notoriously difficult to target by small molecules because Using the parathyroid hormone type 1 receptor (PTHR) as a prototypic class B GPCR target, and a combination of molecular dynamics simulations and elastic network model-based methods, we demonstrate that PTHR precise druggable sites and identify allosteric modulators of PTHR signaling that could be extended to GPCRs

SEPTEMBER 26-29, 2022 (Leipzig, Germany)​ 4GPCRnet meeting bringing together four of the biggest GPCR networks in Europe for a joint meeting in Leipzig. Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded

Loop 2 of the β 2-Adrenergic Receptor Coordinates β-Arrestin Interaction G protein-coupled receptors (GPCRs The β2-adrenergic receptor (β2AR) is a prototypical and extensively studied GPCR that can provide insight into this aspect of GPCR signaling thanks to robust structural data and rich pharmacopeia. regulation that may contribute to biased signaling at GPCRs. We characterized the effects of extracellular loop mutations on agonist-promoted interactions of GPCRs

bilayer creates is dynamic and interactive, becoming the foundation for many interactions involved in GPCR activation of GPCRs2. β-arrestins are cytosolic proteins that translocate to the plasma membrane upon GPCR Understanding the interplay between GPCRs and β-arrestins and how this complex operates on the plasma Membrane phosphoinositides regulate GPCR-β-arrestin complex assembly and dynamics. Molecular mechanism of GPCR-mediated arrestin activation.

Unexpectedly, Class A G protein-coupled receptors (GPCRs), a large class of signaling proteins exemplified transbilayer lipid movement, conceptualized as the swiping of a credit card (lipid) through a card reader (GPCR Conformational changes that facilitate scrambling are distinct from those associated with GPCR signaling In this review, we discuss the physiological significance of GPCR scramblase activity and the modes of

all cytomegalovirus (CMV) genomes analysed to date is the presence of G protein-coupled receptors (GPCR IMPORTANCE G protein-coupled receptors (GPCRs) act as cell surface molecular "switches" which regulate All cytomegalovirus (CMV) genomes analysed to date possess GPCR homologs with phylogenetic evidence for The mouse CMV (MCMV) GPCR homolog, designated M33, is important for cell-associated virus spread and The signalling repertoire of M33 is distinct from cellular GPCRs and little is known of the relevance

Currently, attention was mainly paid to biased signaling modulators targeting G protein-coupled receptors (GPCRs The biased signaling modulation of non-GPCR receptors has yet to be exploited. Toll-like receptor 4 (TLR4) is one such non-GPCR receptor, which involves MyD88-dependent and TRIF-dependent modulators of TLR4 would provide insight for the future development of biased modulators for other non-GPCR

this study was to identify Gα proteins mediating function of neuronal G protein-coupled receptors (GPCRs Some neuronal GPCRs (such as GTR-1, DCAR-1, DOP-2, NPR-8, NPR-12, NPR-9, and DAF-37) functioned upstream of GOA-1, some neuronal GPCRs (such as DCAR-1, DOP-2, NPR-9, NPR-8, and DAF-37) functioned upstream of GSA-1, and some neuronal GPCRs (such as DOP-2, NPR-8, DAF-37, and DCAR-1) functioned upstream of GPA Our results provide clues for understanding the important function of GPCRs-Gα signaling cascade in the

allosteric binding site (IABS) has recently been identified at several G protein-coupled receptors (GPCRs To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs our CCR9-PROTAC is able to reduce CCR9 levels, thereby offering an unprecedented approach to modulate GPCR